Abstract: The preset invention relates to a use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for preventing or treating rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway, particularly rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency.